Is it safe to initiate Entresto (sacubitril/valsartan) in a patient with type II cardiorenal syndrome on maintenance hemodialysis?

Entresto in Type II Cardiorenal Syndrome Patients on Hemodialysis

Entresto (sacubitril/valsartan) can be safely initiated in patients with type II cardiorenal syndrome on maintenance hemodialysis, starting at the lowest dose of 24/26 mg twice daily, with careful monitoring for hyperkalemia and hypotension. 1, 2

Dosing Recommendations for Hemodialysis Patients

Start with 24/26 mg twice daily in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or those on hemodialysis. 1, 2 The FDA label explicitly recommends this reduced starting dose for severe renal impairment, though hemodialysis patients were not studied in PARADIGM-HF. 1, 2

• Titrate slowly with small increments every 1-2 weeks based on tolerability 3
• Target dose achievement is less critical than maintaining therapy—only 14% of hemodialysis patients in observational studies reached maximum dose (97/103 mg twice daily), yet still experienced clinical benefits 4
• Continue beta-blockers and mineralocorticoid receptor antagonists as part of guideline-directed medical therapy when appropriate 5

Evidence Supporting Use in Hemodialysis

Recent observational data demonstrates significant mortality and hospitalization benefits in hemodialysis patients with HFrEF. A 2024 propensity-matched study of 2,868 hemodialysis patients showed sacubitril/valsartan reduced all-cause mortality (HR 0.82,95% CI 0.73-0.92) and all-cause hospitalization (HR 0.86,95% CI 0.79-0.93) compared to ACE inhibitors or ARBs. 4

• Left ventricular ejection fraction improved from 31.3% to 45.1% after one year of treatment in end-stage kidney disease patients 6
• Cardiac remodeling parameters improved significantly, including reductions in left atrial diameter, left ventricular end-diastolic diameter, and improvements in diastolic function 7, 6
• Blood pressure control improved with reductions in both systolic (-11.09 mmHg) and diastolic (-4.37 mmHg) pressures 8

Critical Safety Monitoring

Monitor serum potassium closely—hyperkalemia is the primary safety concern but is manageable with dialysis adjustments. 2

Hyperkalemia Management

• Incidence of hyperkalemia (K >5.5 mEq/L) increases from baseline but severe hyperkalemia remains uncommon (4.2% at 6 months in anuric patients) 9
• Paradoxically, one large study showed reduced hyperkalemia risk compared to ACE inhibitors/ARBs (HR 0.71,95% CI 0.62-0.81) 4
• Check potassium within 1-2 weeks after initiation or dose increase 1
• Adjust dialysate potassium concentration if needed to maintain safe serum levels 5

Hypotension Monitoring

• Symptomatic hypotension occurs in approximately 8-18% of patients but rarely requires discontinuation 2, 10
• Hypotension rates are comparable to ACE inhibitor/ARB therapy in hemodialysis populations 4, 9
• Assess volume status carefully—reduce diuretic doses if applicable, though many hemodialysis patients are anuric 3
• Monitor blood pressure pre- and post-dialysis to identify intradialytic hypotension patterns 5

Renal Function Monitoring

• Serum creatinine increases of >50% occur in approximately 16-17% of patients but are expected with RAAS inhibition 2
• In hemodialysis patients, creatinine changes are less clinically relevant than in non-dialysis populations 5
• Monitor for changes in residual renal function if present 1

Contraindications and Precautions

Do not use Entresto concurrently with ACE inhibitors—a 36-hour washout period is mandatory when switching from an ACE inhibitor. 1, 11, 12 No washout is needed when switching from an ARB. 12

• Absolute contraindication: history of angioedema with ACE inhibitors or ARBs (angioedema risk is 0.5% overall, 2.4% in Black patients) 11, 2
• Avoid in pregnancy or women planning pregnancy 11
• Use caution in patients with severe hepatic impairment (Child-Pugh C)—not recommended as no studies exist 2

Clinical Context for Type II Cardiorenal Syndrome

Type II cardiorenal syndrome (chronic heart failure causing progressive chronic kidney disease) represents an ideal indication for Entresto therapy. 5 The Canadian Cardiovascular Society guidelines specifically recommend initiating or continuing ACE inhibitors and beta-blockers in dialysis patients with HF and LVEF ≤35%, and this recommendation extends to ARNIs as superior alternatives. 5

• Hemodialysis patients with heart failure have a particularly poor prognosis (mean survival ~36 months), making aggressive HF therapy critical 5
• The cardiorenal interaction is bidirectional—improving cardiac function may slow further renal deterioration even in dialysis-dependent patients 5
• Hemodynamic stress and electrolyte shifts during dialysis require close coordination with nephrology 5

Practical Implementation Algorithm

1. Confirm HFrEF diagnosis (LVEF ≤40%) and symptomatic heart failure (NYHA class II-IV) 1, 13
2. Verify no ACE inhibitor use in past 36 hours (or switch from ARB without washout) 12
3. Check baseline potassium <5.5 mEq/L and blood pressure tolerates RAAS inhibition 1, 2
4. Initiate 24/26 mg twice daily 1, 2
5. Recheck potassium and blood pressure in 1-2 weeks 1
6. Titrate by 24/26 mg increments every 1-2 weeks as tolerated, targeting 49/51 mg or 97/103 mg twice daily 1, 3
7. Accept submaximal dosing if needed—clinical benefit occurs across dose ranges 4
8. Continue beta-blockers, SGLT2 inhibitors, and mineralocorticoid receptor antagonists as part of comprehensive GDMT 1

Common Pitfalls to Avoid

• Do not withhold therapy due to dialysis status alone—observational evidence strongly supports use in this population 4, 8, 6
• Do not discontinue prematurely for mild hyperkalemia—adjust dialysate rather than stopping cardioprotective therapy 5, 9
• Do not expect rapid up-titration—most hemodialysis patients require prolonged titration periods and may not reach target doses 4
• Do not assume hypotension will be prohibitive—rates are similar to standard RAAS inhibitors in dialysis populations 4, 9
• Do not forget the 36-hour ACE inhibitor washout—angioedema risk is real and potentially life-threatening 11, 12, 2